CRISPR/Cas9(-3NLS)/sgHMGA2@PDA nanosystem is the potential efficient gene editing therapy for gastric cancer with HMGA2 high expression

Gene therapy is one of the target therapies with promising clinical use for gastric cancer (GC). However, the delivery of the CRISPR/Cas9/sgRNA (RNP) gene editing tool severely limits the practical therapeutic effect of GC. Therefore, it is a great challenge to develop an RNP delivery system that is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhouying, Huo, Xue, Yang, Tingyu, Liu, Kun, Wu, Ting, Feng, Zongqi, Wang, Min, Li, Feng, Jia, Jianchao, Zhang, Xiaoran, Gao, Wenming, Yu, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479195/
https://www.ncbi.nlm.nih.gov/pubmed/36119467
http://dx.doi.org/10.3389/fonc.2022.978533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479195/
https://www.ncbi.nlm.nih.gov/pubmed/36119467
http://dx.doi.org/10.3389/fonc.2022.978533

Ejemplares similares